Posts

Showing posts with the label Primary Sclerosing Cholangitis (PSC) competitive landscape

Primary Sclerosing Cholangitis (PSC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by inflammation and fibrosis of the bile ducts. It is closely linked to inflammatory bowel disease (IBD), and the extent of biliary system involvement can vary. Most PSC patients also have underlying IBD, such as ulcerative colitis or Crohn's disease. Ulcerative colitis is more common in PSC patients, accounting for 85% of cases, whereas Crohn's disease is less prevalent at 15%. Approximately 2.5-7.5% of all ulcerative colitis patients may develop PSC. In over 80% of PSC cases, strictures (narrowing of bile ducts) are present both within and outside the liver. However, around 10% only have intrahepatic strictures, and less than 5% have extrahepatic strictures exclusively. Most individuals with PSC are asymptomatic and are typically diagnosed through abnormal liver function tests in routine blood work. Despite advanced disease, many patients remain symptom-free for extended periods. The clinical cou...

Primary Sclerosing Cholangitis (PSC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by bile duct inflammation and fibrosis and strongly associated with inflammatory bowel disease (IBD). There is variability in the extent of involvement of the biliary system. Most patients with primary sclerosing cholangitis have underlying inflammatory bowel diseases, such as ulcerative colitis or Crohn's disease. Patients with PSC are more likely to have ulcerative colitis than Crohn's disease (85% versus 15%), with approximately 2.5-7.5% of all ulcerative colitis patients having primary sclerosing cholangitis. In more than 80% of patients, the strictures are located in both the intrahepatic and extrahepatic ducts. However, about 10% of these patients have intrahepatic strictures only, while less than 5% will have only extrahepatic strictures. The majority of people with PSC have no symptoms. These patients are typically diagnosed when abnormal biochemical tests of liver function are detected du...